Dalpiciclib combined with pyrotinib and endocrine therapy in women with ER-positive, HER2-positive advanced breast cancer: A prospective, multicenter, single-arm, phase 2 trial

Journal:

PLOS Medicine

Published:

2025-08-01

DOI:

10.1371/journal.pmed.1004669

Affiliations:

9

Authors:

22

Go to article

Institutions	Authors	Share
Fudan University Shanghai Cancer Center (FUSCC), China	5.000000	0.23
Shanghai Medical College (SHMC), Fudan University, China	4.000000	0.18
Harbin Medical University Cancer Hospital, China	3.000000	0.14
Nanchang People’s Hospital, China	3.000000	0.14
Mudanjiang Tumor Hospital, China	2.000000	0.09
Hubei Cancer Hospital (HBCH), China	2.000000	0.09
Hengrui, China	2.000000	0.09
Affiliated Hospital of Nantong University, China	1.000000	0.05

Interested in Oncology and Carcinogenesis?